73 completed, 39 recruiting, 30 unknown, 22 terminated. 83 Phase 1, 80 Phase 2, 22 Not applicable, 16 Phase 3, 5 Early Phase 1.
Follow AML: new trials by email Literature Review of AML trials Research Report on AML
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-Time Breath Analysis in Acute Myeloid Leukaemia for a Rapid Characterisation of Biological Subtypes and to Predict Therapy Responses AML | Not yet recruiting | Jeremy Deuel | 120 | 2026-09-21 | 2026-09-17 | |
| my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults my.naviGATE Digital Tool - Sarcoma, Osteosarcoma | Not applicable | Not yet recruiting | Dana-Farber Cancer Institute | 143 | 2026-08-20 | 2026-04-08 |
| HMA-Venetoclax Induction in Newly Diagnosed AML Azacitidine 75 mg/m² SC/IV Days 1-7 + Venetoclax 400 mg orally Days 1-28 (Cycle 1 ramp-up per institutional TLS protocol); 28-day cycles; maximum 2 induction cycles - AML, AML (Acute Myeloid Leukemia) | Phase 2 | Not yet recruiting | Pakistan Blood and Marrow Transplant (PBMT) Group | 60 | 2026-08-01 | 2026-08-05 |
| Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients Bone Marrow Transplantation, AML | Not yet recruiting | Yasmin medhat munir Mohamed | 300 | 2026-08-01 | 2026-07-10 | |
| A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation TSC-101, Control - AML, MDS | Phase 3 | Active not recruiting | TScan Therapeutics, Inc. | 310 | 2026-06-18 | 2026-10-05 |
| A Study of CRD3874-SI in People With Leukemia CRD3874-SI - Acute Myeloid Leukemia, AML | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2026-06-15 | 2026-09-22 |
| Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML Azacitidine, APG1252 - AML | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 52 | 2026-05-22 | 2026-10-05 |
| Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML Venetoclax, Azacitidine, Liposomal Mitoxantrone - AML | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 27 | 2026-05-08 | 2026-08-07 |
| Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML CAR-T cells chimeric antigen receptor T cells - AML, Refractory/Relapse Acute Myeloid Leukemia | Phase 1 | Recruiting | Peking University People's Hospital | 27 | 2026-05-07 | 2026-06-01 |
| Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML Venetoclax, Azacitidine - AML | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 788 | 2026-04-29 | 2026-04-20 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation - AML, AML (Acute Myeloid Leukemia) | Not applicable | Not yet recruiting | Donghua Zhang | 18 | 2026-01-30 | 2026-01-15 |
| Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT. Bu/Flu/Cy/ATG, Bu/Cy/ATG - AML, Elderly | Not applicable | Recruiting | Peking University People's Hospital | 307 | 2026-01-01 | 2026-09-14 |
| Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity AML, Adult | Recruiting | Fujian Medical University Union Hospital | 405 | 2025-12-01 | 2026-05-14 | |
| Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML Ivosidenib, Venetoclax, Azacitidine - AML, IDH1 Mutation | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 23 | 2025-10-17 | 2026-05-13 |
| A Long Term Follow-up Study of TScan TCR-T Products Observational - AML, ALL | Recruiting | TScan Therapeutics, Inc. | 1000 | 2025-09-09 | 2025-09-10 | |
| QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) Allogeneic TCR-enhanced γδ T cell(QH101), Fludarabine (FLU), Cyclophosphamide (CTX) - MDS, AML | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 9 | 2025-08-15 | 2025-08-20 |
| Leptin: A Marker for AML Chemo-Sensitivity AML, Adult | Recruiting | Fujian Medical University Union Hospital | 86 | 2025-08-01 | 2025-09-09 | |
| A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease Mycophenolate Mofetil, Ruxolitinib - AML | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2025-07-22 | 2026-05-20 |
| The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT Ex-vivo expanded allogeneic γδ T cells - AML (Acute Myelogenous Leukemia), AML | Early Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2025-07-20 | 2025-08-17 |
Showing 20 of 202. Sign in to see all of them.
Leukemia, Myeloid, Acute (68) · Myelodysplastic Syndromes (23) · Leukemia (21) · Recurrence (16) · Hodgkin Disease (14) · Hematologic Neoplasms (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Lymphoma, Non-Hodgkin (11) · Multiple Myeloma (9) · Myeloproliferative Disorders (9) · Neoplasms (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia, Myelomonocytic, Chronic (6) · Lymphoma (6) · Leukemia, Myeloid (5)
Hemic and Lymphatic Diseases (95) · Hematologic Diseases (91) · Neoplasms by Histologic Type (89) · Neoplasms (86) · Leukemia, Myeloid (69) · Leukemia (61) · Pathological Conditions, Signs and Symptoms (38) · Bone Marrow Diseases (37) · Pathologic Processes (37) · Disease Attributes (32) · Immune System Diseases (28) · Immunoproliferative Disorders (26) · Lymphatic Diseases (26) · Lymphoproliferative Disorders (26) · Neoplasms by Site (17)
Cytarabine (29) · Azacitidine (23) · Cyclophosphamide (16) · fludarabine (16) · venetoclax (16) · Daunorubicin (10) · Decitabine (10) · Granulocyte Colony-Stimulating Factor (8) · Idarubicin (8) · Busulfan (7) · fludarabine phosphate (7) · Homoharringtonine (5) · Mitoxantrone (5) · Mycophenolic Acid (5) · Dexamethasone (4)
Institute of Hematology & Blood Diseases Hospital, China (17) · M.D. Anderson Cancer Center (8) · Zhejiang University (8) · Masonic Cancer Center, University of Minnesota (7) · Insel Gruppe AG, University Hospital Bern (4) · PETHEMA Foundation (4) · Beth Israel Deaconess Medical Center (3) · Chinese PLA General Hospital (3) · Massachusetts General Hospital (3) · Nantes University Hospital (3) · TScan Therapeutics, Inc. (3) · The University of Hong Kong (3) · AbbVie (2) · Abramson Cancer Center at Penn Medicine (2) · Actinium Pharmaceuticals (2)
United States (89) · China (51) · France (14) · Germany (13) · Spain (10) · Italy (9) · Australia (7) · Canada (7) · Switzerland (7) · Hong Kong (5) · Netherlands (5) · United Kingdom (5) · Belgium (3) · Greece (2) · Israel (2)
He Huang, MD (4) · Gautam Borthakur, MD (3) · Jianxiang Wang, Dr (3) · Anskar Leung, Professor (2) · Avinash Desai, MD (2) · David E Avigan, MD (2) · David F McDermott, MD (2) · Farhad Ravandi-Kashani, MD (2) · He Huang, PhD (2) · Hui Wei, MD (2) · Jeffrey Miller, MD (2) · Johannes Schetelig, Prof Dr med (2) · Shrikanta Chattopadhyay, MD (2) · Aarthi Shenoy, MD (1)
PMID 17579184, PMID 20673585, PMID 21719884, PMID 22535659, PMID 23012326, PMID 23321953, PMID 23453583, PMID 23909727, PMID 24002496, PMID 24047754, PMID 24573552, PMID 24951467, PMID 25285531, PMID 25599162, PMID 25852054, PMID 26296954, PMID 26858124, PMID 27520294, PMID 27561720, PMID 28129526, PMID 28881839, PMID 29427994, PMID 29859851, PMID 30620383, PMID 31060979, PMID 31175001, PMID 31331399, PMID 32029439, PMID 32264726, PMID 32645016, PMID 32873343, PMID 32929488, PMID 33077867, PMID 33170934, PMID 33394722, PMID 33415416, PMID 33718234, PMID 34439266, PMID 34771451, PMID 34794172, PMID 35274287, PMID 35350938, PMID 35357290, PMID 35829925, PMID 35884458, PMID 37633156, PMID 37838437, PMID 38114624, PMID 38324741, PMID 38896056
2014 (1), 2015 (1), 2023 (1)